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Cellular senescence is a stable cell cycle arrest that inhibits the outgrowth of pre-cancerous cells but is also 
implicated in wound healing, embryonic development, aging and age-related pathologies. Our knowledge on 
gene regulatory circuits that establish and maintain the senescence phenotype is highly fragmentary. Here, we 
provide several lines of evidence supporting a critical and novel function of scaffolding-attachment-factor A 
SAF-A and long, noncoding RNA PANDA in the establishment and maintenance of the senescence phenotype. 
First, we demonstrate that SAF-A and PANDA are differentially expressed in presenescent compared to 
senescent cells. Second, we show that both SAF-A and PANDA actively contribute to senescence induction and 
maintenance. Finally, we establish that SAF-A and PANDA physically and functionally interact to directly 
repress senescence- and proliferation-promoting genes by regulating access of polycomb repressive complexes 
PRC1 and PRC2 as well as transcription factor NF-YA to their cognate target genes. Together, our data identify 
DNA-RNA-binding protein SAF-A and long, noncoding RNA PANDA as key actors in senescence cell fate 
decision and highlight the importance of cell fate dependent target gene changes of transcription factors and 
noncoding RNAs. 
To cite this article: Oliver Bischof, et al. It takes four to tango: Long noncoding RNA PANDA, SAF-A, polycomb repressive 
complexes and NF-Y in senescence regulation. RNA Dis 2015; 2: e855. doi: 10.14800/rd.855. 
Cellular senescence not only plays important roles during 
embryonic development and wound healing, but is also 
considered a major regulator of a number of age-related 
diseases, including cancer [1, 2]. The senescence arrest is 
essentially permanent and accompanied by widespread 
changes in metabolism, cytomorphology, chromatin 
structure, gene expression including a senescence-associated 
secretory phenotype (SASP) - the expression and secretion of 
inflammatory cytokines, growth factors, proteases and other 
molecules that can alter tissue microenvironments.  Among 
the most prominent stimuli that induce a senescence response 
are genomic and epigenomic perturbations caused by 
hyper-activated oncogenes, DNA damage or telomere 
dysfunction [1].  
The senescence response appears to be conserved, at least 
among vertebrate species, and is a doubled-edged sword. On 
the positive side, it protects young organisms from cancer, 
promotes tissue repair, and fine-tunes embryonic 
morphogenesis. On the negative side, it is thought to drive 
late life pathology.  Senescent cells accumulate with age, 
are prominent at sites of many age-related diseases -- both 
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degenerative and hyperplastic -- and likely fuel age-related 
pathology by virtue of the SASP [3].   
One hallmark of senescence is the stable repression of 
proliferation-promoting genes regulated by the E2F-family of 
transcription factors (TFs) [4] and the activation/de-repression 
of senescence-promoting genes that are, at least in part, 
regulated by polycomb-repressive complexes 1 and 2 (PRC1 
and 2) [5]. PRC1 comes in different flavors and three main 
sub-complexes can be distinguished based on the presence 
either of BMI1, MEL18 or NSCP1. The enzymatic center of 
all PRC1 complexes is comprised of the RING1A/B 
ubiquitin ligase that catalyzes the mono-ubiquitination of 
lysine 119 on histone H2A (H2AK119ub) [6]. The core 
component of PRC2 complex is the histone methylase EZH2 
or 1 that catalyzes the di- and tri-methylation of lysine 27 on 
histone H3 (H3K27me3) [7]. Both, H2AK119ub and 
H3K27me3, are associated with transcriptionally inactive 
chromatin. An unresolved question, at least in mammalian 
cells, is the recruitment mechanism of PRCs to their target 
genes because the latter lack a DNA-binding domain and 
thus need to piggy-back on DNA binding factors including 
TFs and noncoding RNAs. 
SAF-A (alias hnRNPU) is a member of ubiquitinously 
expressed heterogeneous nuclear ribonucleoproteins 
(hnRNPs) that also includes the likes of hnRNPA, B and K 
among others [8]. SAF-A was first shown to play a crucial 
role in organization of higher order chromatin structure in the 
interphase nucleus by tethering chromatin loops to nuclear 
matrix via matrix attachment regions (MARs) [9], but it has 
now also been implicated in a diverse array of RNA 
metabolic events including gene regulation and splicing [10]. 
Biochemical studies revealed that SAF-A contains three 
conserved protein domains: a SAF-Box (DNA-binding 
domain), a SPRY-box of unknown function, and an 
RGG-box (RNA binding domain) [11]. Protein-protein 
interaction studies established that SAF-A functions both in 
gene activation and repression. While the gene repressive 
function of SAF-A stems, at least in part, from its interaction 
with HP1α [12] the gene activating function is likely linked to 
its interaction with RNA polymerase II [13, 14], coactivator 
p300 acetyl transferase [15] and BRG1 [16], a member of the 
the ATP-dependent SWI/SNF chromatin-remodeling 
complex. Genome-wide analysis using CLIP-seq revealed 
that SAF-A virtually binds to all classes of regulatory 
noncoding RNAs, including small nuclear RNAs (snRNAs) 
required for splicing [10]. Given SAF-A’s DNA and RNA 
binding domains this makes it a perfect protein to act as an 
adaptor between the DNA and RNA world to direct 
chromatin and gene expression changes. A case in point, 
SAF-A plays a pivotal role for inactivation of the 
X-chromosome (XCI) by facilitating the deposition of 
inactive chromatin marks histone macroH2A, H3K27me3 
and Xist long, noncoding RNA (lncRNA) [17]. 
LncRNAs have emerged as key molecules in the control 
of a wide variety of biological pathways and cellular 
processes [18]. The emerging paradigm is that lncRNAs are 
principal and instructive components of a highly dynamic 
chromatin scaffold that can respond to internal and external 
cues [19]. According to this view lncRNAs are to impact both 
global as well as specific gene expression programs thereby 
shaping cellular diversity and phentoypes.  Many lncRNAs 
are deregulated in human cancers including breast, liver, 
colorectal, prostate and have been found to function as 
oncogenes and tumor suppressors [20-23]. Others and we have 
shown that lncRNAs are also differentially regulated in 
senescence [5,24-26]. The precise function(s) of only a few 
lncRNAs have been defined in these processes. For example, 
lncRNA MALAT1, also known as non-coding nuclear 
enriched abundant transcript 2 (NEAT2), modulates the 
speckle association of splicing factors and is overexpressed 
in many cancer tissues [27, 28]. In line with this, MALAT1 
expression is negatively correlated with senescence [29]. 
Similarly, lncRNAs ANRIL is overexpressed in a subset of 
prostate cancers [30]. ANRIL is expressed from the INK4a 
tumor suppressor gene locus where it facilitates recruitment 
of PRCs and repression of this locus in cis [31,32]. 
Accordingly, ANRIL expression was found to decrease in 
senescent cells concomitant with the derepression of the 
INK4a locus and senescence onset. LncRNA MEG3 is 
repressed in many human cancer cell lines. Forced 
expression of MEG3 inhibited the growth of human cancer 
cell lines suggesting that MEG3 may act as a tumor 
suppressor [33,34]. 7SL lncRNA is highly expressed in cancer 
cells. 7SL silencing was found to promote cell cycle arrest 
and senescence in cancer cells. These effects were mediated, 
at least in part, through binding to and suppressing TP53 
mRNA translation by competing with the RNA-binding 
protein HuR [35]. LncRNA MIR31HG was recently shown to 
control senescence by regulating the expression of 
senescence-promoting gene CDKN2A and a negative 
correlation between lncRNA MIR31HG and CDKN2A 
expression in melanomas exists [25]. Expression correlation 
analyses revealed that lncRNA HOTAIR, encoded in the 
HOXC cluster, is as a strong predictor of breast cancer 
metastasis. The fact that enforced expression of HOTAIR 
was sufficient to drive breast cancer metastasis, involving 
epithelial-to-mesenchymal-ransitions (EMT), support the 
idea that lncRNAs might be involved in cell fate transitions 
in development and in cellular reprogramming [36]. Our own 
studies have established a significant role of PANDA in 
cellular senescence and provided a potential mechanistic link 
RNA & DISEASE 2015; 2: e855. doi: 10.14800/rd.855; © 2015 by Oliver Bischof, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 3 of 5 
 
for PANDA downregulation in hepatocellular carcinoma 
(HCC) [5]. 
The past few years have seen a growing number of 
examples for lncRNAs controlling the access to or 
dissociation of regulatory proteins from chromatin. Several 
studies showed lncRNAs to recruit chromatin 
modifiers/remodellers to regulate transcription [37]. For 
example: the human lncRNA HOTAIR physically associates 
with PRC2 and modulates the localization of PRC2 and 
H3K27me3 at hundreds of sites genome-wide [38]. HOTAIR 
and Xist interface with PRC2 via the catalytic 
methyltransferase subunit EZH2 [39]. Two p53-regulated 
lncRNAs, lncRNA-p21 and PANDA, were recently shown to 
interact with hnRNPK and TF NF-YA, leading to 
transcriptional repression at specific gene loci [40,41]. 
Although many studies initially focused on lncRNAs 
associated with repressive chromatin-modifying complexes, 
it has become evident that active chromatin states are also 
associated with lncRNAs. Recently, novel technologies 
including ChIRP-Seq and CHART-Seq have paved the way 
to decipher genome wide interactions between RNA and 
chromatin with unprecedented precision to reveal genomic 
maps of lincRNA occupancy and general principles of 
RNA-chromatin interactions [42, 43]. Collectively, these 
studies demonstrate the critical importance of lncRNAs in 
chromatin biology to control gene expression. 
Based on the role SAF-A and lncRNAs play in gene 
regulation and tumorigenesis, we recently probed into the 
involvement of these factors in senescence emphasizing on 
their role in transcriptional regulation of 
senescence-promoting and inhibiting genes [5]. We 
demonstrated that both factors, indeed, play a critical role for 
the repression of senescence promoting genes in proliferating 
cells by recruiting BMI1-PRC1 and EZH2-PRC2 to the 
respective gene promoters. In cells undergoing senescence, 
SAF-A:PRC:lncRNA complexes decommission from 
respective targets leading to the de-repression of them. 
Congruent with this, acute depletion of SAF-A impaires the 
association of PRCs with the respective targets and leads to 
de-repression of these genes and induction of senescence. 
Given the RNA and DNA-binding domain of SAF-A we 
speculated that an RNA component could be important for 
the interaction with PRCs. Indeed, we demonstrate that 
specifically the interaction between BMI1:PRC1 is 
RNA-dependent whereas the interaction with EZH2:PRC2 
was not. Subsequently, we identified lncRNA PANDA (p21 
Associated ncRNA DNA damage Activated) [40] as the RNA 
component that mediates SAF-A:BMI1 complex formation 
and recruitment to gene targets. In line with this, PANDA 
depletion, akin to SAF-A depletion, in proliferating cells 
renders them senescent. In addition, we identified 
cyclin-dependent kinase inhibitor CDKN1A (alias p21CIP, 
WAF1) as a crucial target gene for senescence induction and 
congruent with this PANDA-induced senescence could be 
bypassed in CDKN1A-knock-out cells. 
Another important finding of our study was that PANDA 
differentially interacts with protein components in a cell-fate 
dependent manner. PANDA, along with a bevy of other 
lncRNAs (our unpublished data), is strongly up-regulated in 
senescent cells compared to proliferating cells and its 
interaction with SAF-A: PRC1 complex is lost in senescence. 
In senescent cells, however, PANDA takes on another 
function by sequestering transcriptional activator NF-YA 
from proliferation-promoting genes, thus, giving way to their 
repression and enforcing senescence arrest. Hence, silencing 
of PANDA in proliferating and senescent cells has opposite 
outcomes. While in proliferating cells PANDA depletion 
leads to senescence entry by destabilizing PRC function, in 
senescent cells it leads to senescence exit by relieving the 
decoy function on NF-YA. These unique properties suggest 
that PANDA acts as a locking device that confines cells in a 
given proliferative state or cell fate.  
Finally, we unearthed an unexpected role for TF NFYA in 
the regulation of senescence. The histone-like TF NF-Y 
consists of three subunits: NF-YA, NF-YB and NF-YC, 
which are all necessary for DNA binding of CCAAT boxes 
[44]. Loss of function studies highlighted the importance of 
NF-Y in cell cycle progression and NF-Y trimeric complex 
controls the expression of many cell cycle genes in 
collaboration with the E2F family of TFs [45]. As mentioned 
above, in cells undergoing senescence PANDA decoys 
NF-YA from its target genes. We reasoned that ectopic 
expression of NF-YA in senescent cells might override this 
decoy effect and reactivate expression of cell cycle genes to 
force cells back into the cell cycle and proliferation. Indeed, 
this occurred; hence, we identified NF-YA inhibition by 
PANDA as a major senescence-maintaining mechanism.  
Surprisingly, NFYA depletion in senescent cells resulted in 
cell death, thus, bringing forth a novel and unexpected 
function for NFYA in survival of senescent cells. Indeed, 
NF-YA depletion leads to the activation of many 
pro-apoptotic (e.g. TNFα, TNFR1) and repression of many 
anti-apoptotic genes, notably BCL2A1 (our unpublished 
results). This is a very important finding against the backdrop 
of inherent cell death resistance of senescent cells and could 
provide an inroad for future therapy to specifically eliminate 
senescent cells, given that an accumulation of senescent cells 
could have detrimental organismal effects [46]. 
In essence, our study provides compelling evidence that 
long, noncoding RNAs and multimodular DNA: 
RNA-binding proteins, such as SAF-A, mediate widespread 
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PRC and TF recruitment to target genes and are important 
factors for senescence establishment and maintenance.  
Additionally, we are yet to fully appreciate the significance 
of ubiquitously expressed TFs, like the NF-Y complex, in 
many settings, and this argues for a comprehensive 
reassessment of the roles other housekeeping TFs may play 
in cell fate specification. 
Conclusion 
Cellular senescence is increasingly recognized as a major 
contributor to health and disease. As such, research on 
therapeutic strategies exploiting senescence targeting for 
healthspan improvement has gained traction. Importantly, 
elimination of senescent cells in a premature mouse aging 
model was shown to improve overall tissue fitness and 
healthspan [46]. Thus, a detailed understanding of the 
causes/stresses, signalling networks and mechanisms 
underlying cellular senescence is critical to provide inroads 
for new therapeutic strategies to improve health and to target 
hyper/neoplastic and degenerative age-related pathologies 
with the final goal to improve overall healthspan [3].   
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